Sign In
Buy MMSI
$67.27
+0.770 (+1.16%)
At Close: Jun 23, 2026
Merit Medical (MMSI) Hits 52-Week High: What's Driving It?
01:33pm, Monday, 05'th Dec 2022
Investors are optimistic about Merit Medical's (MMSI) slew of product launches.
Merit Medical: Re-Rate To Buy, Upside Potential On Offer
04:45pm, Friday, 02'nd Dec 2022
A Reversal in growth trends across the portfolio, leading to upsides vs. consensus at the top and bottom lines. Strong EPS upside growth forecasted by management into the coming quarters.
Medical Devices Stock Pumps Up Buy Point With New Innovations
05:15pm, Thursday, 17'th Nov 2022
After launching three new products and posting a second quarter of rising EPS growth, medical devices leader Merit Medical Systems is probing a new buy point. The post Medical Devices Stock Pumps Up B
Reasons to Add Merit Medical (MMSI) Stock to Your Portfolio
12:47pm, Thursday, 17'th Nov 2022
Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.
MMSI vs. CNMD: Which Stock Should Value Investors Buy Now?
12:47pm, Monday, 14'th Nov 2022
MMSI vs. CNMD: Which Stock Is the Better Value Option?
Cardiovascular Systems (CSII) Q1 Earnings Miss, Revenues Top
03:26pm, Friday, 11'th Nov 2022 Zacks Investment Research
The launch of the Scoreflex scoring balloon receives a positive response and generates over $1.7 million in sales during the first quarter for Cardiovascular Systems (CSII).
Haemonetics (HAE) Q2 Earnings Beat Estimates, 2023 View Up
02:49pm, Friday, 11'th Nov 2022 Zacks Investment Research
Under the Hospital segment, despite continued macroeconomic, Haemonetics (HAE) meaningfully grows revenues and market share.
BD (BDX) Q4 Earnings and Revenues Beat Estimates, Margins Up
04:16pm, Thursday, 10'th Nov 2022 Zacks Investment Research
The majority of BD's (BDX) core units witness strong revenue growth in the fiscal fourth quarter.
QIAGEN's (QGEN) Q3 Earnings Top Estimates, 2022 View Up
03:43pm, Thursday, 10'th Nov 2022 Zacks Investment Research
The ongoing double-digit sales growth in the non-COVID product portfolio, a high level of profitability and strong cash flow are the major upsides for QIAGEN (QGEN).
STERIS (STE) Q2 Earnings Miss Estimates, Margins Increase
03:31pm, Thursday, 10'th Nov 2022 Zacks Investment Research
Barring AST, poor reported revenue performance across three of STERIS' (STE) operating segments poses concerns.
Surmodics (SRDX) Q4 Earnings and Revenues Top Estimates
01:35pm, Thursday, 10'th Nov 2022 Zacks Investment Research
Surmodics (SRDX) reports a solid fiscal fourth quarter top line on the back of robust Medical Device revenues.
Masimo (MASI) Q3 Earnings Top Estimates, 2022 View Revised
03:38pm, Wednesday, 09'th Nov 2022 Zacks Investment Research
Masimo's (MASI) robust product shipments and continued strength in its healthcare business drive its Q3 sales.
Insulet (PODD) Q3 Earnings Beat Estimates, '22 Sales View Up
02:59pm, Wednesday, 09'th Nov 2022 Zacks Investment Research
Insulet's (PODD) performance benefits from record quarterly U.S. and Total Omnipod new customer starts.
Syneos Health (SYNH) Q3 Earnings Miss Estimates, '22 View Cut
02:52pm, Wednesday, 09'th Nov 2022 Zacks Investment Research
Syneos Health (SYNH) Q3 revenues are below the guidance primarily due to the impact of lower net new business awards, delays in backlog conversion and customer delays in its FSP business.
OPKO Health (OPK) Q3 Earnings Lag Estimates, Revenues Top
01:39pm, Wednesday, 09'th Nov 2022 Zacks Investment Research
OPKO Health's (OPK) third-quarter results reflect dismal segmental performances.
